<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36460480</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e200072</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000200072</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of unknown etiology and poorly understood pathophysiology. There is no specific biomarker either for diagnosis or prognosis. The aim of our study was to investigate differentially expressed proteins in the CSF and serum from patients with ALS to determine their role in the disease process and evaluate their utility as diagnostic or prognostic biomarkers.</AbstractText><AbstractText Label="METHODS">We performed mass spectrometry in the CSF from 3 patients with ALS and 3 healthy controls (HCs). The results were compared with motor cortex dysregulated transcripts obtained from 11patients with sporadic ALS and 8 HCs. Candidate proteins were tested using ELISA in the serum of 123 patients with ALS, 30 patients with Alzheimer disease (AD), 28 patients with frontotemporal dementia (FTD), and 102 HCs. Patients with ALS, AD, and FTD were prospectively recruited from January 2003 to December 2020. A group of age-matched HCs was randomly selected from the Sant Pau Initiative on Neurodegeneration cohort of the Sant Pau Memory Unit.</AbstractText><AbstractText Label="RESULTS">Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and osteopontin (Spp1) were differentially expressed in the CSF and the motor cortex transcriptome of patients with ALS compared with that in HCs (<i>p</i> &lt; 0.05). NOD2 and Spp1 levels were significantly higher in sera from patients with ALS than in HCs (<i>p</i> &lt; 0.001). Receiver operating characteristic analysis showed an area under the curve of 0.63 for NOD2 and 0.81 for Spp1. NOD2 levels were significantly lower in patients with AD and FTD than in patients with ALS (<i>p</i> &lt; 0.0001), but we found no significant differences in Spp1 levels between patients with ALS, AD (<i>p</i> = 0.51), and FTD (<i>p</i> = 0.42). We found a negative correlation between Spp1 levels and ALS functional rating scale (<i>r</i> = -0.24, <i>p</i> = 0.009).</AbstractText><AbstractText Label="DISCUSSION">Our discovery-based approach identified NOD2 as a novel biomarker in ALS and adds evidence to the contribution of Spp1 in the disease process. Both proteins are involved in innate immunity and autophagy and are increased in the serum from patients with ALS. Our data support a relevant role of neuroinflammation in the pathophysiology of the disease and may identify targets for disease-modifying treatments in ALS. Further longitudinal studies should investigate the diagnostic and prognostic value of NOD2 and Spp1 in clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Luna</LastName><ForeName>Noem&#xed;</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbayo</LastName><ForeName>&#xc1;lvaro</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols-Icardo</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turon-Sans</LastName><ForeName>Janina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes-Leiva</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Illan-Gala</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeric&#xf3;</LastName><ForeName>Ivonne</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagola-Lorz</LastName><ForeName>Inma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lleix&#xe0;</LastName><ForeName>Cinta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querol</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio-Guerra</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cort&#xe9;s-Vicente</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Garcia</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Neuromuscular Diseases Laboratory (N.d.C., A.C., D.R.-L., C.L., L.Q., E.C.-V., R.R.-G.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant-Pau), Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER) (N.d.C., A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Madrid; Motor Neuron Diseases Clinic (A.C., J.T.-S., D.R.-L., L.Q., E.C.-V., R.R.-G.), Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Departament de Medicina, Universitat Aut&#xf2;noma de Barcelona; Sant Pau Memory Unit (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED) (O.D.-I., I.I.-G., S.R.-G., D.A., J.F., A.L.), Madrid, Spain; and Neuromuscular and Motor Neuron Diseases Research Group-Health Research Institute of Navarra (IdisNA) (I.J., I.P.-L.). rrojas@santpau.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C429018">NOD2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053473">Nod2 Signaling Adaptor Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506895">SPP1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053473" MajorTopicYN="N">Nod2 Signaling Adaptor Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>21</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36460480</ArticleId><ArticleId IdType="pmc">PMC9720732</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000200072</ArticleId><ArticleId IdType="pii">10/2/e200072</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-172. doi: 10.1056/nejmra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1(5):293-299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Hardiman O, Benatar M, et al. . Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12(3):310-322. doi: 10.1016/s1474-4422(13)70036-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(13)70036-x</ArticleId><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20-38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksoy YA, Deng W, Stoddart J, et al. . Stressed out: the role of FUS and TDP-43 in amyotrophic lateral sclerosis. Int J Biochem Cell Biol. 2020;126:105821. doi: 10.1016/j.biocel.2020.105821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2020.105821</ArticleId><ArticleId IdType="pubmed">32758633</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin A, Perera ND, Beart PM, Turner BJ, Shabanpoor F. Amyotrophic lateral sclerosis and autophagy: dysfunction and therapeutic targeting. Cells. 2020;9(11):2413. doi: 10.3390/cells9112413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9112413</ArticleId><ArticleId IdType="pmc">PMC7694295</ArticleId><ArticleId IdType="pubmed">33158177</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson N, Facciponte D, Bradley W, Stommel E. Cytokine expression levels in ALS: a potential link between inflammation and BMAA-triggered protein misfolding. Cytokine Growth Factor Rev. 2017;37:81-88. doi: 10.1016/j.cytogfr.2017.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.05.001</ArticleId><ArticleId IdType="pubmed">28532674</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, et al. . Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):15295. doi: 10.1038/s41598-020-72247-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Y, Han F. Key mechanisms and potential targets of the NLRP3 inflammasome in neurodegenerative diseases. Front Integr Neurosci. 2020;14:37. doi: 10.3389/fnint.2020.00037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnint.2020.00037</ArticleId><ArticleId IdType="pmc">PMC7393579</ArticleId><ArticleId IdType="pubmed">32792920</ArticleId></ArticleIdList></Reference><Reference><Citation>Illan-Gala I, Alcolea D, Montal V, et al. . CSF sAPP&#x3b2;, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91(17):e1619-e1628. doi: 10.1212/wnl.0000000000006383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000006383</ArticleId><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Verde F, Fang L, et al. . Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018;89(3):239-247. doi: 10.1136/jnnp-2017-317138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Thezenas ML, et al. . Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 2018;83(2):258-268. doi: 10.1002/ana.25143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25143</ArticleId><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Clarim&#xf3;n J, Carmona-Iragui M, et al. . The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a dataset for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement (N Y). 2019;5:597-609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6804606</ArticleId><ArticleId IdType="pubmed">31650016</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Martinez-Lage P, Sanchez-Juan P, et al. . Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85(7):626-633. doi: 10.1212/wnl.0000000000001859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000001859</ArticleId><ArticleId IdType="pubmed">26180139</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbero F, Michelini S, Moriones OH, et al. . Role of common cell culture media supplements on citrate-stabilized gold nanoparticle protein corona formation, aggregation state, and the consequent impact on cellular uptake. Bioconjug Chem. 2022;33(8):1505-1514. doi: 10.1021/acs.bioconjchem.2c00232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.2c00232</ArticleId><ArticleId IdType="pubmed">35852911</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Berrocoso T, Llombart V, Colas-Campas L, et al. . Single cell immuno-laser microdissection coupled to label-free proteomics to reveal the proteotypes of human brain cells after ischemia. Mol Cell Proteomics. 2018;17(1):175-189. doi: 10.1074/mcp.ra117.000419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.ra117.000419</ArticleId><ArticleId IdType="pmc">PMC5750846</ArticleId><ArticleId IdType="pubmed">29133510</ArticleId></ArticleIdList></Reference><Reference><Citation>Simats Oriol A. Potential Terap&#xe8;utic de Nous Biomarcadors d'isqu&#xe8;mia Cerebral. Universitat Aut&#xf2;noma de Barcelona Departament de Bioqu&#xed;mica i Biologia Molecular; 2018. hdl.handle.net/10803/662614.</Citation></Reference><Reference><Citation>Dols-Icardo O, Montal V, Sirisi S, et al. . Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e829. doi: 10.1212/nxi.0000000000000829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/nxi.0000000000000829</ArticleId><ArticleId IdType="pmc">PMC7371375</ArticleId><ArticleId IdType="pubmed">32669313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi: 10.1212/wnl.0b013e31821103e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(pt 9):2456-2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87(6):628-632. doi: 10.1136/jnnp-2015-310998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Martinez DA, Nunez-Avellaneda D, Castanon-Sanchez CA, Salazar MI. NOD2: activation during bacterial and viral infections, polymorphisms and potential as therapeutic target. Rev Invest Clin. 2018;70(1):18-28. doi: 10.24875/ric.17002327.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/ric.17002327</ArticleId><ArticleId IdType="pubmed">29513298</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9(10):995-1007. doi: 10.1016/s1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNair L, Xiao S, Miletic D, et al. . MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis. Brain. 2016;139(1):86-100. doi: 10.1093/brain/awv308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv308</ArticleId><ArticleId IdType="pubmed">26525917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Zhang M, Zhang L, et al. . Intracellular osteopontin stabilizes TRAF3 to positively regulate innate antiviral response. Sci Rep. 2016;6(1):23771. doi: 10.1038/srep23771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23771</ArticleId><ArticleId IdType="pmc">PMC4824456</ArticleId><ArticleId IdType="pubmed">27026194</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud FJ, Du Y, Greif E, et al. . Osteopontin/secreted phosphoprotein-1 behaves as a molecular brake regulating the neuroinflammatory response to chronic viral infection. J Neuroinflammation. 2020;17(1):273. doi: 10.1186/s12974-020-01949-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01949-4</ArticleId><ArticleId IdType="pmc">PMC7499959</ArticleId><ArticleId IdType="pubmed">32943056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Ren Physiol. 2001;280(4):F667-F674. doi: 10.1152/ajprenal.2001.280.4.f667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.2001.280.4.f667</ArticleId><ArticleId IdType="pubmed">11249858</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchibori T, Matsuda K, Shimodaira T, Sugano M, Uehara T, Honda T. IL-6 trans-signaling is another pathway to upregulate Osteopontin. Cytokine. 2017;90:88-95. doi: 10.1016/j.cyto.2016.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2016.11.006</ArticleId><ArticleId IdType="pubmed">27863335</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto T, Imagama S, Hirano K, et al. . CD44 expression in astrocytes and microglia is associated with ALS progression in a mouse model. Neurosci Lett. 2012;520(1):115-120. doi: 10.1016/j.neulet.2012.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2012.05.048</ArticleId><ArticleId IdType="pubmed">22634473</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikodemova M, Small AL, Smith SM, Mitchell GS, Watters JJ. Spinal but not cortical microglia acquire an atypical phenotype with high VEGF, galectin-3 and osteopontin, and blunted inflammatory responses in ALS rats. Neurobiol Dis. 2014;69:43-53. doi: 10.1016/j.nbd.2013.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.11.009</ArticleId><ArticleId IdType="pmc">PMC4079765</ArticleId><ArticleId IdType="pubmed">24269728</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Liao B, et al. . Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun. 2011;25(5):1025-1035. doi: 10.1016/j.bbi.2010.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Sharma A, Mishra P, et al. . Chitotriosidase&#x2013;a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics. 2013;10(1):19. doi: 10.1186/1559-0275-10-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>von Neuhoff N, Oumeraci T, Wolf T, et al. . Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS One. 2012;7(9):e44401. doi: 10.1371/journal.pone.0044401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044401</ArticleId><ArticleId IdType="pmc">PMC3435306</ArticleId><ArticleId IdType="pubmed">22970211</ArticleId></ArticleIdList></Reference><Reference><Citation>Manberg A, Skene N, Sanders F, et al. . Altered perivascular fibroblast activity precedes ALS disease onset. Nat Med. 2021;27(4):640-646. doi: 10.1038/s41591-021-01295-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>